Breakthrough Therapy: 'A Lower Bar Of Evidence'?
Executive Summary
MedPAC meeting elicits negative view of designation from one members and no one disagreed. Should US FDA reiterate what the special designation actually means?
You may also be interested in...
Gottlieb Defends Accelerated Approval, Scorns Access Limits By Payors
US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, arguing coverage limits on AA products are not in the interest of public health.
Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
ICER Hemophilia Gene Therapy Reviews Show Clear ‘Net Health Benefit’ But Caution On Patient, Payer Fronts Given Upfront Costs
Restrictive interpretations of FDA labels for BioMarin and CSL Behring products by payers could signal slow launch of gene therapies seeking to supplant existing treatments.